Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
SGMT
#3724
Sagimet Biosciences Inc. Series A Common Stock
5.5
4
USD
+2.21%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+2.21%
Changement Mensuel
+5.32%
Evolution sur 6 mois
-26.43%
Changement Annuel
+135.74%
Clôture Précédente
5.4
2
Open
5.5
4
Bid
Ask
Low
5.5
4
High
5.5
4
Volume
90
Marchés
Actions des Marchés US
Soins de Santé
SGMT
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2023
2024
2025
TTM
Key stats
Total common shares outstanding
31.91 M
32.2 M
32.59 M
—
Valuation ratios
Enterprise value
—
—
—
—
Price to earnings ratio
-2
-3.1
-3.75
-13.51
Price to sales ratio
27.88
—
—
—
Price to cash flow ratio
-2.35
-3.32
-4.19
-15.65
Price to book ratio
0.61
0.91
1.72
2.69
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.29
-0.28
-0.44
-0.38
Return on equity %
-0.31
-0.29
-0.46
-0.4
Return on invested capital %
-65.77 K
-4 254.01
-5 896
—
Gross margin %
100
—
—
—
Operating margin %
-1 537
—
—
—
EBITDA margin %
-1 538.85
—
—
—
Net margin %
-1 393.8
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
17.09
34.3
22.82
73.84
Inventory turnover
—
—
—
—
Asset turnover
0.02
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-2.27
-1.35
-1.41
-1.41
EBIT per share
-2.94
—
—
—
EBITDA per share
-2.94
—
—
—
Total debt per share
—
—
—
—
Cash per share
9.07
5.06
3.5
16.06
Net current asset value per share
9.24
4.87
3.6
15.77
Tangible book value per share
8.71
4.97
3.44
15.48
Working capital per share
8.7
4.73
3.44
14.88
Book value per share
8.71
4.97
3.44
15.48
Nouvelles
Citizens réitère sa recommandation sur Sagimet Biosciences après les progrès MASH
Citizens reiterates Sagimet Biosciences stock rating on MASH progress
Oppenheimer réitère sa recommandation sur Sagimet après les progrès de l’essai MASH
Oppenheimer reiterates Sagimet stock rating on MASH trial progress
L’action Sagimet en hausse après des données de sécurité positives pour son médicament contre l’acné
Sagimet stock rises after positive Phase 3 safety data for acne drug
Ascletis reports positive long-term safety data for acne drug denifanstat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)
Sagimet reports positive Phase 1 results for MASH combination therapy
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Le président exécutif de Sagimet Biosciences vend des actions pour 290.000€
Sagimet Biosciences executive chairman sells $290k in shares